Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants

• 2023

  Sign in to bookmark this resource.

  Sign in
• Simon Drysdale; Katrina Cathie; Florence Flamein; Markus Knuf; Andrea Collins; Helen Hill
PMID: 38157500DOI: https://dx.doi.org/10.1056/NEJMoa2309189

---

Access Resources

• Journal ArticleEN

About

This article discusses a study on nirsevimab, a monoclonal antibody used to prevent hospitalizations due to RSV in infants. It was tested on 8,058 infants in France, Germany, and the UK. The results showed that nirsevimab reduced RSV-related hospitalizations by 83.2% compared to standard care. It also decreased severe cases needing oxygen support by 75.7%. The study found no major safety concerns with nirsevimab use and suggests it could help reduce the burden of RSV hospitalizations among infants during their first season of exposure to the virus.

---

Tags

Hazard: Infectious Disease

Audience: Physicians

Emergency Management Stage: Preparedness (Prevention / Protection)

Collection: Niresivemab Library

Keywords: France; Germany; Hospitalization; Infant; Respiratory Syncytial Virus Infections; Respiratory Tract Infections; United Kingdom; Respiratory Syncytial Virus, Human; Antibodies, Monoclonal, Humanized

Institutions: St. George's University Hospitals NHS Foundation Trust; University Hospital Southampton NHS Foundation Trust; Liverpool University Hospitals Foundation NHS Trust; Sanofi; Université Paris-Saclay; Assistance Publique - Hôpitaux de Paris (AP-HP)

---

More like this

Universal Infant Immunisation Against Respiratory Syncytial Virus and European Inequalities: The Pandemics Lesson has not been Learnt 2023 · Hôpital Antoine-Béclère AP-HP, Université Paris-Saclay, American College of Emergency Physicians, Hospital General Universitario Gregorio Marañón, St. Marien Children's Hospital, University Medical Centre Utrecht, Respiratory Syncytial Virus NETwork (ReSViNET) Foundation, University Hospital of Padova Evaluation of Antibody-Based Preventive Alternatives for Respiratory Syncytial Virus: A Novel Multi-Criteria Decision Analysis Framework and Assessment of Nirsevimab in Spain 2024 · University Carlos III, BioMad, Fisabio-Public Health, Catholic University of Valencia, Instituto de Salud Carlos III, Weber Foundation Pediatric Behavioral Health During the COVID-19 Pandemic: Expert Advice for Preparedness, Response, and Recovery 2023 · Pediatric Pandemic Network (PPN), University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---